Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

April 4, 2021

Study Completion Date

July 5, 2021

Conditions
Covid19
Interventions
DRUG

intermediate dose Enoxaparin/ unfractionated heparin

Intermediate dose anticoagulation according to creatinine clearance and weight

DRUG

standard prophylactic dose Enoxaparin/ unfractionated heparin

Standard prophylaxis anticoagulation according to creatinine clearance and weight

DRUG

Atorvastatin 20mg

Statin

DRUG

Matched placebo

Matched placebo to atorvastatin 20 mg

Trial Locations (1)

199691110

Masih Daneshvari Hospital, Tehran

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Tehran Heart Center

OTHER

collaborator

Masih Daneshvari Hospital

OTHER

collaborator

Hazrat Rasool Hospital

OTHER

collaborator

Modarres Hospital

OTHER

collaborator

Firuzgar hospital affiliated to Iran University of Medical Sciences

OTHER

collaborator

Imam Khomeini Hospital

OTHER

collaborator

Sina Hospital, Iran

OTHER

collaborator

Tabriz University of Medical Sciences

OTHER

collaborator

Shariati Hospital

OTHER

collaborator

Imam Ali Hospital

UNKNOWN

collaborator

Labbafinejhad Hospital

OTHER

lead

Rajaie Cardiovascular Medical and Research Center

OTHER

NCT04486508 - Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 | Biotech Hunter | Biotech Hunter